- Takeda also is suing for patent infringement, with the dispute centering on Mylan’s launch of generic colchicine, Colcrys’s active ingredient, before it had permission to do so, according to Mylan’s expedited
requestfor confidential treatment, filed Monday in federal court in Wilmington, Delaware
- Takeda also filed sealed complaint, filing says
- Takeda and Mylan reached confidential settlement and license
agreementsin December 2017 in another Delaware case; the agreements also ended a related patent-infringement...
Dec. 2, 2019, 11:14 PM